chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Shot was given on 05/20/2003. On 05/26/2003, donor c/o being sick at stomache and H/A. Initially claimed s/sx were b/c of tetanus shot, present today stating he had virus and wants to donate.
About 12 hours after dos Chills, fatigue, nausea. Last for 9 hours. Then better.
Flu like,  severe chest pain, palpitations, higher bp, breathing problems, brain seizures, loss of taste, sneezing, coughing, stuffy nose, confusion, extreme fatigue, fever, chills, sore throat, ringing in ears, headaches, muscle and jaw pain for 3 months and counting!!! What is in this vaccine?!!!!! It's poison!
Information has been received from a nurse referring to the patients of unknown age and gender. The patients' medical histories, concurrent conditions and concomitant therapies were not reported. The doses of GARDASIL 9 were improperly stored at 1.5 Celsius degree for 29 minutes on 15-AUG-2016. Prior excursions included 10.2 Celsius degree for 6 hours 35 minutes on 21-JUN-2016 and 1.4 Celsius degree for 53 minutes on 09-AUG-2016. On unknown dates in 2016 (reported as "after 15-AUG-2016"), the patients were vaccinated with improperly stored GARDASIL 9 (0.5 ml, lot # M014929, expiration date 27-MAY-2017, route not reported). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
This spontaneous report as received from a nurse refers to a patent of unknown age and gender. There was no information about patient's concomitant medications, pertinent medical history, drug reactions and allergies provided. On 22-JUL-2015, the patient was vaccinated with an improperly stored GARDASIL 9 (lot# K026246, expiration date 28-JAN-2017, dose, frequency, route and site of administration were not reported). The vaccine was exposed to temperatures outside of the recommended range. No adverse experiences were reported. This is one of several reports received from the same reporter. Additional information has been requested.
It was reported that a pt (7 of 10) received a Fluzone SV '00-'01 on 10/9/00. Reportedly, within 48-72 hours, post vax, the pt complained of pain, redness, swelling and induration at the injection site. No specifics provided; further information requested.
Information regarding Prevnar was received from an investigator regarding a 14 month old male participant in a study who experienced neutropenia and dehydration. At 5 months of age, the participant received the third dose on 1/5/01. The participant also received the third dose of Hib-Titer Vaccine, the third dose of poliomyelitis vaccine inactivated, the third dose of Hepatitis B vaccine and the third dose of Diphtheria/Tetanus Toxoids/Acellular Pertussis vaccine on 1/5/01. The patient's concurrent illnesses include asthma, wheezing, upper respiratory tract infection (since 9/18/01 with symptoms of runny nose, fever, and slight cough), viral infection (since 9/21/01), pyrexia (seen in the emergency room on 9/22/01) and oral intake reduced (seen in the emergency room on 9/22/01). Indication for Prevnar was immunization. Product was administered on 1/5/01. Dose regimen was 1 dose. Concomitant therapy included Prevnar, Poliomyelitis vaccine inactivated, Hib-Titer vaccine, Hepatitis B vaccine and Diphtheria/Tetanus Toxoids/Acellular Pertussis Vaccine. The patient was admitted to the hospital on 9/23/01 for neutropenia and dehydration. Lab test results revealed a decreased white blood cell count of 1.5 K/uL (6.0-17.0), decreased platelet count of 107 K/uL (140-400) and a normal neutrophil percentage of 38% (16-60). Bone marrow aspiration was normal. No recurrence of the neutropenia or thrombocytopenia was noted. The patient recovered (date unspecified). The assessments of the investigator and medical monitor for dehydration were unknown. The investigator considered neutropenia possibly related to the study product as well as study protocol. The medical monitor considered neutropenia not related to the study product but related to concurrent viral illness.
21MAR96 reported rash lt scapula w/6" x 6" also lt deltoid edematous & reddened @ 4"x 4" w/bluish discoloration in center @ 1" in diameter;pt reports joint pain in both hands w/tingling
Three hours post vax, the pt developed a high temperature and rash. The pt sought unspecified medical attention.
This is spontaneous report from a non-contactable Consumer reporting for her son. A male patient of an unspecified age and ethnicity received TRUMENBA, via an unspecified route of administration on an unspecified date at single dose. The patient medical history and concomitant medications were not reported. The patient experienced chills and drowsy on the same unspecified date of vaccine administration with outcome of not recovered. The patient received ADVIL and TYLENOL to treat the events. No Follow-up attempts possible. No further information expected.
A friend of the patient called us today to inform us that the patient had recently passed away from a brain aneurysm. The friend asked it it were possible that this occurrence was somehow related to patient receiving his covid vaccination. The friend did not have a lot of information about the occurrence; he only stated that the patient's brain aneurysm was about 6 weeks after his 2nd dose of the covid vaccine. Patient was not a regular patient of ours so we have no additional medical history for him. We administered his first Moderna vaccine on 4-2-2021, and he returned for his second dose on 4-30-2021. I assured the friend I would report this to VAERS and thanked him for reaching out to us on behalf of patient.
husband also got the COVID-19; This spontaneous case was reported by a patient family member or friend and describes the occurrence of COVID-19 (husband also got the COVID-19) in a male patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form On an unknown date, received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) dosage was changed to 1 dosage form, dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) dosage was changed to 1 dosage form and dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. and dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (husband also got the COVID-19). At the time of the report, COVID-19 (husband also got the COVID-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: Positive.         No concomitant medications were reported.  The reporter stated that the patient had none but some mild symptoms of COVID-19, not recently and the reporter was not sure about which medication did the physician prescribed to the patient but believed that it was Paxlovid.   This case was linked to US-MODERNATX, INC.-MOD-2021-385994 (E2B Linked Report).   Reporter did not allow further contact; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-385994:Wife's case, same reporter
Swelling of the left side of the face.  Instructed to take NSAIDS when needed.
Patient received ZOSTAVAX or 6/5/12, left arm returned to clinic 6/7/12 with extreme redness at site raised, firm to touch, very hot to touch. Treated with BACTRIM DS one po BID x 10 days, and pt instructed to take MOTRIN po which she did not take. Returned to clinic 6/8/12 site, appears improved, photo taken.
Instant rash in and around injection site. Hives and red rinsen patches on leg.
a medication error with PENTACEL described as only the liquid DTap-IPV portion was given and not the Hib portion due to the products not being mixed with no reported adverse event; Initial information received on 27-Jul-2022 regarding an unsolicited valid  non-serious case received from a nurse .  This case involves a 8 months old male patient and it reported a medication error with Pentacel described as only the liquid Dtap-ipv portion was given and not the hib portion due to the products not being mixed with no reported adverse event , for receiving vaccine DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included PNEUMOCOCCAL VACCINE CONJ (PNEUMOCOCCAL CONJUGATE VACCINE).  On 25-Jul-2022, the patient received  a dose of 0.5 ml (once) of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE , (lot: UJ577AA ; expiry date: 10-Sep-2022)   in unknown administration site for immunization.  It was reported that a medication error with Pentacel described as only the liquid dtap-ipv portion was given and not the hib portion due to the products not being mixed with no reported adverse event (product preparation error) following the administration of DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE.  Action taken: not applicable.  Outcome: unknown   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Vials were initially stored in refrigerator on 22-Aug-2022 and administered on 23-Sep-2022; No Adverse event; patient given vaccine after BUD date; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (patient given vaccine after BUD date), PRODUCT STORAGE ERROR (Vials were initially stored in refrigerator on 22-Aug-2022 and administered on 23-Sep-2022) and NO ADVERSE EVENT (No Adverse event) in a 1-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR9237B) for COVID-19 prophylaxis.     The patient's past medical history included COVID-19 on 01-Jul-2022. Previously administered products included for Product used for unknown indication: Flu quadrivalent injectable pfree (Lot: UT7682MA, intramuscular, Left thigh and dose 3.) on 30-Aug-2022. Past adverse reactions to the above products included No adverse event with Flu quadrivalent injectable pfree.    On 23-Sep-2022 at 4:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter. On 23-Sep-2022 at 4:00 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (patient given vaccine after BUD date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vials were initially stored in refrigerator on 22-Aug-2022 and administered on 23-Sep-2022) and NO ADVERSE EVENT (No Adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (patient given vaccine after BUD date), PRODUCT STORAGE ERROR (Vials were initially stored in refrigerator on 22-Aug-2022 and administered on 23-Sep-2022) and NO ADVERSE EVENT (No Adverse event) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-Jul-2022, SARS-CoV-2 test: Positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered NO ADVERSE EVENT (No Adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (patient given vaccine after BUD date) and PRODUCT STORAGE ERROR (Vials were initially stored in refrigerator on 22-Aug-2022 and administered on 23-Sep-2022).    No concomitant medication was reported.  Vaccine coordinator was calling to report that some patients (Adults and Pediatrics) received expired Moderna COVID-19 vaccine after 30 days beyond use date (22-Sep-2022). Date the vial was initially stored in the refrigerator was 22 AUG 2022.  There were unbroken cartons. Vial size for 6 months to 5 years.  The vial did not undergo any temperature excursions.  No treatment information was provided.
Vaginal yeast infection; Approximately two weeks after that, she again developed a yeast infection, and again two weeks after that.; Approximately two weeks after that, she again developed a yeast infection, and again two weeks after that.; This case was reported by a consumer via call center representative and described the occurrence of vaginal yeast infection in a 10-year-old female patient who received Hepatitis B vaccine for prophylaxis.   On an unknown date, the patient received the 3rd dose of Hepatitis B vaccine. On an unknown date, between 1 and 2 weeks after receiving Hepatitis B vaccine, the patient experienced vaginal yeast infection, vaginal yeast infection and vaginal yeast infection. The patient was treated with miconazole nitrate (Monistat). On an unknown date, the outcome of the vaginal yeast infection was recovered/resolved and the outcome of the vaginal yeast infection and vaginal yeast infection were unknown.   It was unknown if the reporter considered the vaginal yeast infection, vaginal yeast infection and vaginal yeast infection to be related to Hepatitis B vaccine.  Additional details were provided as follows: The case was reported by patient's parent. The age at vaccination was not unknown. The patient received a dose of Hepatitis B vaccine in 2019 and approximately 1 to 2 weeks after her vaccination, developed a vaginal yeast infection and approximately two weeks after that, she again developed a yeast infection, and again two weeks after that. The patient was 10 years old at the time and had not started her periods. The patient was treated with Monistat. The reporter was not certain of the manufacturer. The reporter was given medical advice disclaimer. The reporter was referred to Heath care professional. The reporter was offered as per package insert. The reporter did not wish to provide last name or address and only provided limited information. The reporter stated that she might be contacted via phone or text but did not consent for health care professional to follow-up. This is 1 of 2 cases reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022011309:Same reporter
suspected vaccination failure; flare ups; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.  The patient's past medical history included shingles.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows The patient had reported for him/herself. The age at vaccination was not reported. The patient had more flare ups of shingles since he/she got Shingles vaccine than he/she ever had before. The patient regretted getting Shingles vaccine. This case was considered as suspected vaccination failure, since the details regarding the completion of the primary immunization, time to onset for event and laboratory confirmation of shingles were not provided.
Patient came into office 5/31/19 @ 3:23pm For an MMR vaccination per Dr. After giving the vaccine patient cried then was standing with her mom at the front desk & fell to the floor. Eyes were fixed arms stiff above head lasting 1 minute. 911 was called she was brought to hospital.
Information has been received from a mother concerning her son patient who on an unspecified date was vaccinated with a dose of MMR II (dose and route unspecified). The mother reported that "The MMR II vaccine injured my son". At the time of the report the outcome of the patient was unknown. It was unspecified if the patient sought medical attention. No further information is available.
Per office visit assessment, vaccine reaction lt thigh, most of thigh area red warm to touch, cries when leg moved.
Hospitalization for COVID-19 on dates 8/21/2023- 8/22/2023. Treated with no COVID-related medications.
Rash on foot. Treatment: 3ml of children's BENADRYL by mouth in office.
Before getting my 4th booster shot I received a 2nd dose of the shingle  vaccine on  12/01/2022.  I received my 4th Moderna Bivalent Booster on 10/10/2022. On 09/19/2022 I visited my doctor for a yearly check-up. She referred me to get my mammograms  done. I scheduled my  Screening Mammograms  on  12/05/2022 at 06:30pm. When  I got my Screening Mammograms done they notified me that my first Mammograms was suspicious. They advised me to reschedule a second  Diagnostic Mammograms  and an Ultra Sound so I scheduled it for 12/23/2022.  When the second Mammograms were done . They gave me the results right way and  told that my Mammograms were normal . I didn't need to get the Ultra Sound done anymore.
shingles; Information has been received from a lawyer regarding a case in litigation concerning a patient of unknown age and gender. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication.  On or about 12-SEP-2012, the patient was inoculated with a dose of zoster vaccine live (ZOSTAVAX) (lot number, dosage and route of administration were not provided) at pharmacy by a pharmacist, for the long-term prevention of shingles and/or zoster-related conditions. On an unspecified date, the patient was treated by a healthcare provider for herpes zoster. As a direct and proximate result of patient's use of the Zoster Vaccine Live(ZOSTAVAX) vaccine, patient would continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization (on unspecified dates), physician care, monitoring, treatment, medications, and supplies. At the time of report, the patient was not recovered from herpes zoster. The reporter considered the adverse events to be related to Zoster Vaccine Live(ZOSTAVAX).
Nausea; Headache; Dizziness; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness), NAUSEA (Nausea) and HEADACHE (Headache) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Feb-2021, the patient experienced DIZZINESS (Dizziness), NAUSEA (Nausea) and HEADACHE (Headache). At the time of the report, DIZZINESS (Dizziness), NAUSEA (Nausea) and HEADACHE (Headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. No treatment related information has been reported.
Nurse providing vaccines and leading bandaid/recorder: RN Nurse witness and assist with bandaid: RN Client involved:  Witness present: Client's mother  8/16/23 at 10:55am, client was brought back to office, verified name and DOB, client had no allergies or PMH, and vaccines were starting to be administered. Client was to receive following: COVID BV, Polio, MMR, Hepatitis B peds, TDAP, and Varicella. After 5 vaccines were administered (Varicella NOT administered), client stated he was feeling dizzy. Client had pallor, stated he had blurry vision and stated he was dizzy. Client looked diaphoretic. RN paused providing the Varicella vaccine, and immediately grabbed an ice pack and applied it to the back of client's neck. RN also had a fan available and started having that blow on client's face. RN asked client if he had eaten anything. Client stated around 8am he had a piece of toast. RN provided client with a graham cracker snack to start eating. Client stated he wanted water, RN was able to provide small bottle of water. RN grabbed blood pressure cuff and purple chair for client. Bandaid was sent at 11:03am (phone system not set up and unable to call overhead). Client's BP was taken at 11:08am and was 105/64, HR 64, RR 14. Client's BP was taken second time at 11:11am, 100/60, HR 76, RR 12. Client stated he was starting to feel better. Bandaid was completed at 11:15am. Client sat in chair until 11:30, at which point client's color had returned to face, diaphoresis had resolved, and client stated vision was no longer blurry and client was no longer dizzy. Client and mother were counseled for client to eat large meal, hydrate well, and get good night's sleep before next appointment, to aid in preventing episode from happening again. Client verbalized understanding. Client and mother were counseled to inform nurse at next appointment about this episode, so that nurse would be able to prepare for potential episode. Client and mother verbalized understanding of all aforementioned information.
Received the vaccine & the next day became very weak and ill with throwing up. Her sister came to visit and noticed her right face was drooping & her balance was off so she called ambulance.  Subsequently has been hospitalized for a month with a heart failure exacerbation that has led to ICU care, sepsis with Klebsiella pneumonia, acute kidney injury now with long term dialysis, hyponatremia, & elevated liver enzymes